Retinal Optical Coherence Tomography in Neuromyelitis Optica
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received March 23, 2021
- Accepted in final form June 15, 2021
- First Published September 15, 2021.
Author Disclosures
- Frederike Cosima Oertel, MD/PhD,
- Svenja Specovius, MSc,
- Hanna G. Zimmermann, PhD,
- Claudia Chien, PhD,
- Seyedamirhosein Motamedi, PhD,
- Charlotte Bereuter, BSc,
- Lawrence Cook, PhD,
- Marco Aurélio Lana Peixoto, MD, PhD,
- Mariana Andrade Fontanelle, MD,
- Ho Jin Kim, MD, PhD,
- Jae-Won Hyun, MD, PhD,
- Jacqueline Palace, MD,
- Adriana Roca-Fernandez, MSc,
- Maria Isabel Leite, MD, PhD,
- Srilakshmi Sharma, MD, PhD,
- Fereshteh Ashtari, MD,
- Rahele Kafieh, PhD,
- Alireza Dehghani, PhD,
- Mohsen Pourazizi, PhD,
- Lekha Pandit, MD, PhD,
- Anitha D'Cunha, PhD,
- Orhan Aktas, MD,
- Marius Ringelstein, MD,
- Philipp Albrecht, MD,
- Eugene May, MD,
- Caryl Tongco,
- Letizia Leocani, MD, PhD,
- Marco Pisa, MD,
- Marta Radaelli, MD, PhD,
- Elena H. Martinez-Lapiscina, MD, PhD,
- Hadas Stiebel-Kalish, MD,
- Sasitorn Siritho, MD,
- Jérome de Seze, MD, PhD,
- Thomas Senger, MD,
- Joachim Havla, MD,
- Romain Marignier, MD, PhD,
- Alvaro Cobo Calvo, MD, PhD,
- Denis Bichuetti, MD, PhD,
- Ivan Maynart Tavares, MD, PhD,
- Nasrin Asgari, MD, PhD,
- Kerstin Soelberg, MD,
- Ayse Altintas, MD,
- Rengin Yildirim, MD,
- Uygur Tanriverdi, MD,
- Anu Jacob, MD,
- Saif Huda, MD, PhD,
- Zoe Rimler, BSc,
- Allyson Reid, MD,
- Yang Mao-Draayer, MD, PhD,
- Ibis Soto de Castillo, MD,
- Axel Petzold, MD, PhD,
- Ari J. Green, MD,
- Michael R. Yeaman, MD, PhD,
- Terry Smith, MD,
- Alexander U. Brandt, MD* and
- Friedemann Paul, MD*
- Frederike Cosima Oertel, MD/PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
American Academy of Neurology National Multiple Sclerosis Society (US)
NONE
NONE
NONE
NONE
NONE
NONE
- Svenja Specovius, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hanna G. Zimmermann, PhD,
NONE
NONE
(1) Bayer Healthcare, Speaker Honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claudia Chien, PhD,
NONE
NONE
Bayer speaker honorarium unrelated to current study.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Novartis research support unrelated to current study.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Seyedamirhosein Motamedi, PhD,
NONE
NONE
NONE
NONE
Co-inventor on patent applications for retinal optical coherence tomography image analysis, unrelated to this work
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Einstein Junior Scholarship from Einstein Foundation Berlin
NONE
NONE
NONE
NONE
NONE
NONE
- Charlotte Bereuter, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lawrence Cook, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) Centers for Disease Control: U01CE002855, PI, three years; 2) Utah Highway Safety Office, PI, three years; 3) Utah Department of Transportation, PI, two years; HRSA, statistician, three years
NONE
1) Four Corners Youth Consortium; 2) Guthy-Jackson Charitable Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Marco Aurélio Lana Peixoto, MD, PhD,
(1) Advisory board of Gilenya (Novartis) in Brazil(2) Advisory board of Ocrelizumab (Roche) in Brazil
NONE
Funding for travel from Novartis Funding for travel from Biogen
(1)Arquivos de Neuro-Psiquiatria - Member of the Advisory Editorial Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Support for paper publication from Roche
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Mariana Andrade Fontanelle, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ho Jin Kim, MD, PhD,
Roche, Sanofi Genzyme and Viela Bio
NONE
Received travel expenses and/or honoraria for lectures or educational activities from Alexion, Biogen, Celltrion, Eisai, GC Pharma, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva-Handok, and Viela Bio
Multiple Sclerosis Journal, Coeditor, 2019 Journal of Clinical Neurology, Associate Editor, 2016
NONE
NONE
NONE
Aprilbio, Daewoong, HanAll BioPharma, MDimune, Merck Serono, Roche, Sanofi Genzyme, UCB, and Viela Bio
NONE
NONE
NONE
NONE
National Research Foundation of Korea, 2018R1A5A2023127, , Co-Principal Investigator, 2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jae-Won Hyun, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Research Foundation of Korea, NRF- 2020R1F1A1072174, principal investigator, 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jacqueline Palace, MD,
All commercial (advisory boards last 2 years) 1) Merck Serono 2) Roche 3) ARGENX 4) Novartis 5) UCB 6) Alexion 7) Vitaccess 8) Syneos 9) Janssen
NONE
All commercial (speakers/meetings honorarium last two years) 1) Merck Serono 2) Viela Bio 3) Roche 4) Alexion 5) Amplo 6) Syneos
NONE
ISIS Innovation Ltd. To protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis. Reference EP2812690B1
NONE
NONE
All commercial (advisory boards last two years) 1) Merck Serono 2) Roche 3) ARGENX 4) Novartis 5) UCB 6) Alexion 7) Vitaccess 8) Syneos 9) Janssen Commercial (consultancy) 1) Merck Serono 2) UCB 3) Roche 4) Alexion 5) Argenx 6) Syncona 7) Impulze 8) PRMA 9) Amplo
Please see 3 (speaker/meetings)
NONE
NONE
All commercial (support for research) 1) Merck Serono 2) MedImmune 3) Amplo 4) Alexion
NONE
NONE
Grant for research: 1) Multiple Sclerosis Society 2) Medical Research Council 3) MyWare Clinical Training Fellowship 4) SPARKS Great Ormond Street
NONE
NONE
NONE
NONE
NONE
NONE
- Adriana Roca-Fernandez, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
Perspectum Ldt, Biomarker scientist, 1 year and 6 months
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Isabel Leite, MD, PhD,
NONE
NONE
Dr. Maria Isabel Leite is supported by NHS National Specialised Commissioning Group for Neuromyelitis Optica, UK, and by NIHR Oxford Biomedical Research Centre, and has received travel grant and speaking honoraria from Biogen Idec and travel grant from Novartis.
Neuromuscular Disorders, editorial board member, from January 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Srilakshmi Sharma, MD, PhD,
NONE
NONE
Janssen Novartis Allergan Honororarium for speaking
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institute of Health Research UK May 2021-May 2024 UK Medical Research Council April 2021- September 2022 MR/T024682/1
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fereshteh Ashtari, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rahele Kafieh, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alireza Dehghani, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mohsen Pourazizi, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lekha Pandit, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anitha D'Cunha, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Orhan Aktas, MD,
NONE
NONE
(1) Bayer, speaker honoraria (2) Novartis, speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck Serono, travel and speaker honoraria (5) Teva, speaker honoraria (6) Sanofi-Genzyme, speaker honoraria (7) Roche, travel and speaker honoraria (8) Almirall, speaker honoraria (9) Alexion, travel and speaker honoraria (10) Celgene, travel and speaker honoraria (11) Viela Bio, travel support
(1) PLoS ONE, Academic Editor, since 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis
(1) German Ministry of Science (BMBF), PI for NationNMO/KKNMS (NationNMO‐PAT FKZ 01GI1602B), since 2016
(1) German Research Foundation (DFG), PI in GRK2578, since 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marius Ringelstein, MD,
1. Roche Pharma GmbH, served on a national scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.
NONE
1. Alexion, speaking honorarium. 2. Roche,speaking honorarium and funding for travel to a conference. 6. Biogen Idec, funding for travel to a conference.
NONE
NONE
NONE
NONE
1. Roche Pharma GmbH, served on a national and international scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Philipp Albrecht, MD,
(1) Novartis, serving on an advisory board; (2) Biogen, serving on an advisory board; (3) Ipsen, serving on an advisory board; (4) Merck, serving on an advisory board; (5) Merz, serving on an advisory board; (6) Roche, serving on an advisory board; (7) Allergan, serving on an advisory board; (8) Celgene, serving on an advisory board
NONE
(1) Novartis, travel/accommodation/meeting expenses and speaker honoraria; (2)Teva, travel/accommodation/meeting expenses and speaker honoraria; (3) Biogen, travel/accommodation/meeting expenses and speaker honoraria; (4) Merz Pharmaceuticals, travel/accommodation/meeting expenses, (5) Ipsen, travel/accommodation/meeting expenses; (6) Esai, travel/accommodation/meeting expenses; (7) Glaxo Smith Kline, travel/accommodation/meeting expenses; (8) Bayer Healthcare, speaker honoraria, travel/accommodation/meeting expenses; (9) Allergan, speaker honoraria, travel/accommodation/meeting expenses; (10) Celgene, travel/accommodation/meeting expenses;
(1) BMC Neuroscience, associate editor (2) Frontiers in Neurology, associate editor (3) Journal of Clinical Medicine, associate editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen (2) Novartis (3) Merz Pharmaceuticals (4) Ipsen (5) Roche (6) Allergan (7) Celgene
European Fund For Regional Development (EFRE.NRW)
NONE
(1) Doktor Robert Pfleger Stiftung (2) Iselore Luckow Stiftung (3) Europäischer Fonds für Forschung und Regionale Entwicklung (EFRE)
NONE
NONE
NONE
NONE
NONE
NONE
- Eugene May, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Caryl Tongco,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Letizia Leocani, MD, PhD,
(1) Merck KGaA
NONE
(1) Roche, travel support (2) Merck Serono, travel support
(1) European Journal of Neurology, Associate Editor, 2020, (2) Frontiers in Neurology, Associate Editor, 2018, (3) CLinical Neurophysiology Practice, Associate Editor, 2016, (4) Neurological Sciences, Associate Editor, 2018 (5) Neurophysiologie Clinique, Associate Editor, 2020
NONE
NONE
NONE
(1) Merck KGaA, (2) Roche, (3), Biogen, (4) Bristol-Meyer Squibb, (5) Almirall
(1) Med-Ex
NONE
NONE
(1) Biogen, (2) Novartis, (3) Merck KGaA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marco Pisa, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marta Radaelli, MD, PhD,
I have partecipated in advisory board for Biogen, Merck Serono
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elena H. Martinez-Lapiscina, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Before 16th April 2019, Elena Martinez-Lapiscina (all funds to the institution) has received grants from Instituto de Salud Carlos III, Spain JR16/000016, PI17/01228, RD16/0015/0003.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hadas Stiebel-Kalish, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sasitorn Siritho, MD,
NONE
NONE
Dr. Siritho has received funding for travel and speaker honoraria from Merck Serono, Pacific Healthcare (Thailand), Menarini (Thailand), Biogen Idec, UCB (Thailand),Eisai and Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
ORACLE study from Merck Serono being evaluating physician 150 dollar TOWER study from Sanofi Aventis for being evaluating physician 600 dollar
NONE
Siriraj Hospital, Mahidol University grants R015232060 for 200,000 baht
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jérome de Seze, MD, PhD,
None
NONE
None
Revue Neurologique
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Senger, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joachim Havla, MD,
(1) Novartis Pharma (2) Merck Group (3) Roche (4) Sanofi Genzyme (5) Biogen (6) Alexion
NONE
(1) Merck Group (2) Biogen (3) Novartis Pharma (4) Roche (5) Celgene
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
JH reports a grant for OCT research from Merck. JH reports a grant for PMS research from Merck.
I am (partially) funded by the German Federal Ministry of Education and Research (Grant Numbers 01ZZ1603[A-D] and 01ZZ1804[A-H] (DIFUTURE)).
NONE
Friedrich-Baur Foundation, Germany Guthy-Jackson Charitable Foundation, USA
NONE
NONE
NONE
NONE
NONE
NONE
- Romain Marignier, MD, PhD,
Dr Marignier is serving on a scientific advisory board of Viela Bio and UCB
NONE
Romain Marignier has received lecturing fees and travel grants from Biogen, Novartis, Roche, Sanofi, Alexion, UCB
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alvaro Cobo Calvo, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Denis Bichuetti, MD, PhD,
Advisory Board: Janssen
NONE
NONE
Neuroimmunology Reports, Editorial Board, since 2020
NONE
NONE
NONE
Scientific Advisory Council Member, non profit, Amigos Multiplos Pela Esclerose International Clinical Consortium Member, non profit, The Guthy Jackson Charitable Foundation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ivan Maynart Tavares, MD, PhD,
NONE
NONE
NONE
(1) Arquivos Brasileiros de Oftalmologia, editorial advisory board member, current (2) Revista Brasileira de Oftalmologia, associate editor, current
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) CNPq, Ministry of Science and Technology of Brazil, 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nasrin Asgari, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The University of Southern Denmark, 2016 Region of Southern Denmark, 2017
The University of Southern Denmark
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kerstin Soelberg, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ayse Altintas, MD,
For Merck and Deva pharmaceutical companies as a scientific advisory board member
NONE
From Generica and TEVA, travel grants were received
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rengin Yildirim, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Uygur Tanriverdi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anu Jacob, MD,
Novartis Roche
NONE
Viela Bio , Alexion Roche and Novartis
NONE
NONE
NONE
NONE
Roche
Veila Bio, Novartis , Roche
NONE
NONE
NONE
UK NHS -NMO service
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Saif Huda, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NMOSD UK
NONE
NONE
NONE
NONE
NONE
NONE
- Zoe Rimler, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Allyson Reid, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yang Mao-Draayer, MD, PhD,
Acorda, Bayer Pharmaceutical, Biogen Idec, EMD Serono, Sanofi-Genzyme, Novartis, Celgene/Bristol Myers Squibb, Roche-Genentech, Janssen, Questor, Chugai, and Teva Neuroscience
NONE
Acorda, Bayer Pharmaceutical, Biogen Idec, EMD Serono, Sanofi-Genzyme, Novartis, Celgene/Bristol Myers Squibb, Roche-Genentech, Janssen, Questor, Chugai, and Teva Neuroscience
NONE
NONE
NONE
NONE
Acorda, Bayer Pharmaceutical, Biogen Idec, EMD Serono, Sanofi-Genzyme, Novartis, Celgene, Roche-Genentech, Questor, Chugai, and Teva Neuroscience
Teva neuroscience, Biogen Idec, Janssen, EMD Serono,
NONE
NONE
NONE
NIH NIAID Autoimmune Center of Excellence: UM1-AI110557; 1UM1AI144298; NIH NINDS R01-NS080821
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ibis Soto de Castillo, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Axel Petzold, MD, PhD,
Advisory board on optical coherence tomography in MS (OCTiMS, CNF2333A2301), Novartis. SC for ZEISS Angi network.
NONE
NONE
NONE
NONE
Internuclear ophthalmoparesis Evidence-Based Medicine  UpToDate 2020
NONE
NONE
Heidelberg Spectralis Academy.
The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
NONE
NONE
NONE
NONE
The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
NONE
NONE
NONE
NONE
NONE
NONE
- Ari J. Green, MD,
Medimmune End Point adjudication committee, Novartis Pharmaceuticals OCTIMS steering committee, Inception 5 Sciences Advisor and Steering Committee, Pipeline Pharmaceuticals Advisor, Bionure Scientfic Advisory Board
NONE
NONE
JAMA Neurology Associate Editor Neurology Editorial Board December 2010-2015
Remyelination molecules and pathways Eye movement monitoring for MS
NONE
NONE
Pipeline Therapeutics
NONE
NONE
NONE
NONE
NINDS R01 NS088155 NIA 2R01AG038791-06A1 NIH R01 NS105741
NONE
National MS Society Sherak Foundation Hellman Foundation
Pipeline Bionure
NONE
NONE
NONE
NONE
Mylan Pharmaceuticals/Synthon/Pharmasciences v Teva Pharmaceuticals Expert Witness
- Michael R. Yeaman, MD, PhD,
(1) Guthy-Jackson Charitable Foundation (2) Scientific Advisory Committee, Genentech-Roche (3) Scientific Advisor, Alexion (4) Scientific Advisor, Horizon
NONE
NONE
(1) PLoS Pathogens, Associate Editor, 2014-2020
(1) Vaccines targeting drug-resistant pathogens (2) Immunotherapies targeting drug-resistant pathogens (3) Novel anti-infective biological therapeutics (4) Novel anti-infective small molecules (5) Novel biologicals regulating programmed cell death
NONE
NONE
(1) Consultant, Genentech-Roche (1) Consultant, Alexion (1) Consultant, Horizon (2) Advisor, Guthy-Jackson Charitable Foundation
NONE
NONE
NONE
NONE
(1) United States Department of Defense (2) United States National Institutes of Health
NONE
NONE
Metacin, Inc.
NONE
NONE
NONE
NONE
NONE
- Terry Smith, MD,
NONE
Horizon Therapeutics
Horizon Therapeutics, Guthy Jackson Foundation
NONE
US patents covering inhibition of IGF-I receptor as therapy for autoimmune diseases
NONE
NONE
Horizon Therapeutics
Horizon Therapeutics
Advisor, Guthy Jackson Charitable Foundation
NONE
NONE
NONE
Frederick G.L. Huetwell Professor
Bell Charitable Foundation RPB Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Alexander U. Brandt, MD* and
Serves on the observational study monitoring board of the CAVS study.
NONE
NONE
NONE
(1) Patents issued and pending on Perceptive Visual Computing based Motor Function Analysis (2) Patents issued and pending on retinal image analysis (3) Patent on Multiple Sclerosis Serum Biomarker
NONE
NONE
NONE
NONE
(1) Serves on the executive board of IMSVISUAL
(1) UCI MS Center, Optical coherence tomography (2) Charité ECRC, Optical coherence tomography
NONE
(1) BMWi, ZIM KF2443803KJ, PI, two years (2) BMWi, ZIM KF2291305AK3, Co-I, one year (3) BMWI, EXIST-FT 03EFEBE079, PI, two years (4) BMBF, NEU2 N2-ADVISIMS, Co-I, three years
NONE
(1) The Guthy Jackson Charitable Foundation Stock/Stock Options, Medical Equipment & Materials: (1) Motognosis GmbH, 2014 (ongoing) (2) Nocturne GmbH, 2018 (ongoing)
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD*
Novartis OCTIMS study steering committee MedImmune / Viela Bio steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, Celgene
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- From the Experimental and Clinical Research Center (F.C.O., Svenja Specovius, H.G.Z., C.C., S.M., C.B., A.U.B., F.P.), Max Delbrück Center for Molecular Medicine and Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany: NeuroCure Clinical Research Center (F.C.O., Svenja Specovius, H.G.Z., C.C., S.M., C.B., A.U.B., F.P.), Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Germany; Department of Neurology (F.C.O., A.J.G.), University of California San Francisco, CA; Department of Pediatrics (L.C.), University of Utah, Salt Lake City; CIEM MS Research Center (M.A.L.P., M.A.F.), University of Minas Gerais, Medical School, Belo Horizonte, Brazil; Department of Neurology (H.J.K., J.-W.H.), National Cancer Center, Goyang, Republic of Korea; Department of Neurology (J.P., A.R.-F., M.I.L.), and Department of Ophthalmology (Srilakshmi Sharma), and Department of Ophthalmology (Srilakshmi Sharma), Oxford University Hospitals, National Health Service Trust, UK; Kashani MS Center (F.A.), School of Advanced Technologies in Medicine and Medical Image and Signal Processing Research Center (R.K.), Department of Ophthalmology, Isfahan Eye Research Center (A.D., Mohsen Pourazizi), Isfahan University of Medical Sciences, Iran; Department of Neurology (L.P., A.D'C.), KS Hegde Medical Academy, Nitte University, Mangalore, India; Department of Neurology (O.A., Marius Ringelstein, P.A.), Medical Faculty, Heinrich Heine University Düsseldorf, Germany; Swedish Neuroscience Institute Neuro-Ophthalmology (E.M., C.T.), Seattle, WA; Experimental Neurophysiology Unit (L.L., Marco Pisa, Marta Radaelli), Institute of Experimental Neurology (INSPE) Scientific Institute Hospital San Raffaele and University Vita-Salute San Raffaele, Milan, Italy; Hospital Clinic of Barcelona-Institut d'Investigacions (E.H.M.-L.), Biomèdiques August Pi Sunyer, (IDIBAPS), Spain; Sackler School of Medicine (H.S.-K.), Tel Aviv University, Israel; Neuro-Ophthalmology Division (H.S.-K.), Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel; Division of Neurology (Sasitorn Siritho), Department of Medicine, Siriraj Hospital and Bumrungrad International Hospital, Bangkok, Thailand; Neurology Service (J.d.S., Thomas Senger), University Hospital of Strasbourg, France; Institute of Clinical Neuroimmunology (J.H.), Biomedical Center and University Hospital, Ludwig-Maximilians Universitaet Muenchen, Munich, Germany; Neurology (R.M., A.C.C.), Multiple Sclerosis, Myelin Disorders and Neuroinflammation, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, France; Centre d'Esclerosi Múltiple de Catalunya (Cemcat) (A.C.C.), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Department of Neurology and Neurosurgery (D.B., I.M.T.), Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil; Departments of Neurology (N.A.), Slagelse Hospitals, Institute of Regional Health Research, University of Southern Denmark, Odense; Institute of Regional Health Research (N.A., K.S.), University of Southern Denmark, Odense; Department of Neurology (A.A., U.T.), and Department of Ophthalmology (R.Y.), Cerrahpasa Medical Faculty, Istanbul University, Turkey; The Walton Centre for Neurology and Neurosurgery (A.J., S.H.), Liverpool, UK; The Cleveland Clinic Abu Dhabi (A.J.), United Arab Emirates; NYU Multiple Sclerosis Comprehensive Care Center (Z.R., A.R.), Department of Neurology, NYU School of Medicine, New York; Department of Neurology (Y.M.-D.), University of Michigan Medical School, Ann Arbor; Department of Neurology (I.S.C.), Hospital Clínico de Maracaibo, Venezuela; Moorfield's Eye Hospital (A.P.), University College London, UK; Department of Medicine (M.R.Y.), Los Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA, United States of America; Department of Medicine (M.R.Y.), David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America; Departments of Ophthalmology and Visual Sciences (Terry Smith), Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, United States of America; Division of Metabolism (Terry Smith), Endocrine and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor; Department of Neurology (A.U.B.), University of California, Irvine; and Department of Neurology (F.P.), Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
- Correspondence
Dr. Paul friedemann.paul{at}charite.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.